GB201900702D0 - Therapy - Google Patents

Therapy

Info

Publication number
GB201900702D0
GB201900702D0 GBGB1900702.0A GB201900702A GB201900702D0 GB 201900702 D0 GB201900702 D0 GB 201900702D0 GB 201900702 A GB201900702 A GB 201900702A GB 201900702 D0 GB201900702 D0 GB 201900702D0
Authority
GB
United Kingdom
Prior art keywords
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1900702.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Priority to GBGB1900702.0A priority Critical patent/GB201900702D0/en
Publication of GB201900702D0 publication Critical patent/GB201900702D0/en
Priority to PCT/GB2020/050097 priority patent/WO2020148548A1/en
Priority to US17/422,739 priority patent/US12544460B2/en
Priority to JP2021541198A priority patent/JP7587506B2/ja
Priority to EP24212299.2A priority patent/EP4516915A3/en
Priority to AU2020208997A priority patent/AU2020208997B2/en
Priority to EP20701850.8A priority patent/EP3911368A1/en
Priority to CN202080016138.4A priority patent/CN113543814B/zh
Priority to CA3126429A priority patent/CA3126429A1/en
Priority to CN202510707055.4A priority patent/CN120683181A/zh
Priority to JP2024167091A priority patent/JP7835461B2/ja
Priority to US18/949,585 priority patent/US20250064984A1/en
Priority to AU2026201536A priority patent/AU2026201536A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB1900702.0A 2019-01-18 2019-01-18 Therapy Ceased GB201900702D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1900702.0A GB201900702D0 (en) 2019-01-18 2019-01-18 Therapy
CN202510707055.4A CN120683181A (zh) 2019-01-18 2020-01-17 用于治疗肾病综合征的aav基因疗法
EP20701850.8A EP3911368A1 (en) 2019-01-18 2020-01-17 Aav gene therapy for treating nephrotic syndrome
US17/422,739 US12544460B2 (en) 2019-01-18 2020-01-17 AAV gene therapy for treating nephrotic syndrome
JP2021541198A JP7587506B2 (ja) 2019-01-18 2020-01-17 ネフローゼ症候群を処置するためのａａｖ遺伝子療法
EP24212299.2A EP4516915A3 (en) 2019-01-18 2020-01-17 Aav gene therapy for treating nephrotic syndrome
AU2020208997A AU2020208997B2 (en) 2019-01-18 2020-01-17 AAV gene therapy for treating nephrotic syndrome
PCT/GB2020/050097 WO2020148548A1 (en) 2019-01-18 2020-01-17 Aav gene therapy for treating nephrotic syndrome
CN202080016138.4A CN113543814B (zh) 2019-01-18 2020-01-17 用于治疗肾病综合征的aav基因疗法
CA3126429A CA3126429A1 (en) 2019-01-18 2020-01-17 Aav gene therapy for treating nephrotic syndrome
JP2024167091A JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのａａｖ遺伝子療法
US18/949,585 US20250064984A1 (en) 2019-01-18 2024-11-15 Aav gene therapy for the kidney
AU2026201536A AU2026201536A1 (en) 2019-01-18 2026-02-27 AAV gene therapy for treating nephrotic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1900702.0A GB201900702D0 (en) 2019-01-18 2019-01-18 Therapy

Publications (1)

Publication Number Publication Date
GB201900702D0 true GB201900702D0 (en) 2019-03-06

Family

ID=65528327

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1900702.0A Ceased GB201900702D0 (en) 2019-01-18 2019-01-18 Therapy

Country Status (8)

Country Link
US (2) US12544460B2 (https=)
EP (2) EP4516915A3 (https=)
JP (2) JP7587506B2 (https=)
CN (2) CN113543814B (https=)
AU (2) AU2020208997B2 (https=)
CA (1) CA3126429A1 (https=)
GB (1) GB201900702D0 (https=)
WO (1) WO2020148548A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
GB202003109D0 (en) 2020-03-04 2020-04-15 Univ Bristol Gene therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202009039D0 (en) 2020-06-15 2020-07-29 Univ Bristol Therapy
GB202103470D0 (en) * 2021-03-12 2021-04-28 Univ Bristol Promoter
CN114592052A (zh) * 2022-04-01 2022-06-07 中国人民解放军陆军军医大学第二附属医院 一种肾病综合征患者pdss2致病突变基因及其检测试剂
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression
WO2025072667A2 (en) * 2023-09-29 2025-04-03 University Of Utah Research Foundation Compositions and methods for treating phosphomannomutase 2 (pmm2) deficiency
CN117871216B (zh) * 2024-03-12 2024-06-04 中日友好医院(中日友好临床医学研究所) 一种石蜡标本中肾小球裂隙膜的三维可视化方法
GB202414499D0 (en) * 2024-10-02 2024-11-13 Purespring Therapeutics Ltd Methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
FR2804127B1 (fr) * 2000-01-20 2004-12-24 Inst Nat Sante Rech Med Gene srn1 implique dans le syndrome nephrotique cortico- resistant, proteine codee par ce gene et utilisations diagnostiques et therapeutiques
WO2003082305A1 (en) 2002-04-03 2003-10-09 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2007125723A1 (ja) 2006-04-28 2007-11-08 Osaka University 糸球体スリット蛋白誘導剤
CN120174012A (zh) 2013-10-24 2025-06-20 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
HK1249534A1 (zh) 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
US20190022250A1 (en) 2015-11-06 2019-01-24 National University Corporation Kumamoto University Pharmaceutical composition for preventing or treating heart failure
WO2017144080A1 (en) * 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells
MX2019001920A (es) 2016-08-19 2019-07-01 Curevac Ag Arn la terapia contra el cancer.
WO2018144709A2 (en) 2017-02-01 2018-08-09 The Trustees Of The University Of Pennsylvania Gene therapy for treating citrullenemia
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression

Also Published As

Publication number Publication date
JP2022517407A (ja) 2022-03-08
EP4516915A2 (en) 2025-03-05
CN113543814B (zh) 2025-06-17
JP7835461B2 (ja) 2026-03-25
EP4516915A3 (en) 2025-07-09
US20220125950A1 (en) 2022-04-28
US12544460B2 (en) 2026-02-10
CA3126429A1 (en) 2020-07-23
WO2020148548A1 (en) 2020-07-23
AU2026201536A1 (en) 2026-03-19
JP7587506B2 (ja) 2024-11-20
AU2020208997A1 (en) 2021-08-05
JP2025011130A (ja) 2025-01-23
US20250064984A1 (en) 2025-02-27
AU2020208997B2 (en) 2025-12-11
CN120683181A (zh) 2025-09-23
EP3911368A1 (en) 2021-11-24
CN113543814A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
GB201804255D0 (en) Macrophage-based therapy
IL277336A (en) combined treatment
GB201900702D0 (en) Therapy
GB201819853D0 (en) Therapy
ZA202200731B (en) Combination therapy
IL280729A (en) Combined treatment
IL279908A (en) Combined treatment
SG11202101518QA (en) Combination therapy
GB201918752D0 (en) New therapy
GB201912191D0 (en) New therapy
GB201817385D0 (en) Therapy
GB201914006D0 (en) Combination Therapy
GB201910473D0 (en) Combination therapy
GB201906864D0 (en) Combination therapy
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
GB201919036D0 (en) Therapy
GB201916983D0 (en) Therapy
GB201914848D0 (en) Therapy
GB201913797D0 (en) Therapy
GB201913785D0 (en) Therapy
GB201912524D0 (en) Therapy
GB201911948D0 (en) Therapy
GB201911064D0 (en) Therapy
GB201919301D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)